Better Birth Control Exists, But Big Pharma Isn’t Interested

Bloomberg (08/08/2019)
  • Almost 60 years later, the contraceptive pill remains largely the same.
  • Big Pharma has focused on new life-saving treatments (more profitable).
  • In 2018, US cancer drug sales totaled $58.4B vs $5.4B for contraceptives.
  • High safety hurdles also make contraceptives a lawsuit target.
  • However, San Diego-based Evofem Biosciences developed Amphora, a birth-control gel that can be applied 1 hour before sex without the pill’s side-effects (headaches, bloating, etc).
  • Amaphora keeps vaginal pH low and inhospitable for sperm.
  • Evofem plans to release Amphora mid-2020 for $140-170 per month.